Recursion Pharmaceuticals (NASDAQ:RXRX) and Acrivon Therapeutics (NASDAQ:ACRV) Head to Head Survey
by Renee Jackson · The Cerbat GemAcrivon Therapeutics (NASDAQ:ACRV – Get Free Report) and Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.
Insider & Institutional Ownership
71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 11.9% of Acrivon Therapeutics shares are owned by insiders. Comparatively, 8.4% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Acrivon Therapeutics and Recursion Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Acrivon Therapeutics | N/A | -54.10% | -48.67% |
| Recursion Pharmaceuticals | -863.37% | -63.98% | -47.05% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Acrivon Therapeutics and Recursion Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Acrivon Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
| Recursion Pharmaceuticals | 1 | 2 | 2 | 0 | 2.20 |
Acrivon Therapeutics presently has a consensus price target of $11.67, suggesting a potential upside of 602.81%. Recursion Pharmaceuticals has a consensus price target of $9.40, suggesting a potential upside of 189.23%. Given Acrivon Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Acrivon Therapeutics is more favorable than Recursion Pharmaceuticals.
Volatility & Risk
Acrivon Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, Recursion Pharmaceuticals has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.
Earnings & Valuation
This table compares Acrivon Therapeutics and Recursion Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Acrivon Therapeutics | N/A | N/A | -$80.56 million | ($2.13) | -0.78 |
| Recursion Pharmaceuticals | $74.68 million | 22.95 | -$644.76 million | ($1.48) | -2.20 |
Acrivon Therapeutics has higher earnings, but lower revenue than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Acrivon Therapeutics beats Recursion Pharmaceuticals on 9 of the 13 factors compared between the two stocks.
About Acrivon Therapeutics
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.